Advanced search
Publication Cover
Cell Cycle Volume 14, 2015 - Issue 15
Submit an article Journal homepage
1,254
Views
20
CrossRef citations to date
0
Altmetric
Report

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells

Mala K TalekarDivision of Oncology & Stem Cell Transplant; The Children's Hospital of Philadelphia; Philadelphia, PAUSA
,
Joshua E AllenOncoceutics, Inc.; Hummelstown, PAUSA
,
David T DickerLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Oncology and Molecular Therapeutics Program; Fox Chase Cancer Center; Philadelphia, PAUSA
&
Wafik S El-DeiryLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Oncology and Molecular Therapeutics Program; Fox Chase Cancer Center; Philadelphia, PAUSACorrespondence[email protected]
Pages 2422-2428 | Received 11 May 2015, Accepted 18 May 2015, Published online: 26 Jun 2015

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sarah E. Paraghamian, Jianqing Qiu, Gabrielle M. Hawkins, Ziyi Zhao, Wenchuan Sun, Yali Fan, Xin Zhang, Hongyan Suo, Tianran Hao, Varun Vijay Prabhu, Joshua E. Allen, Chunxiao Zhou & Victoria Bae-Jump. (2023) A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer. Cancer Biology & Therapy 24:1.
Read now
Varun V. Prabhu, Mala K. Talekar, Amriti R. Lulla, C. Leah B. Kline, Lanlan Zhou, Junior Hall, A. Pieter J. Van den Heuvel, David T. Dicker, Jawad Babar, Stephan A. Grupp, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jeffrey J. Pu, David F. Claxton, Nadia Khan, Wolfgang Oster, Joshua E. Allen & Wafik S. El-Deiry. (2018) Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle 17:4, pages 468-478.
Read now

Articles from other publishers (18)

Chukwuyem Ekhator, Ramin Rak, Ramya Tadipatri, Ekokobe Fonkem & Jai Grewal. (2022) A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults. Cureus.
Crossref
Emily M. J. Fennell, Lucas J. Aponte‐Collazo, Joshua D. Wynn, Kristina Drizyte‐Miller, Elisa Leung, Yoshimi Endo Greer, Paul R. Graves, Andrew A. Iwanowicz, Hani Ashamalla, Ekhson Holmuhamedov, Henk Lang, Donald S. Karanewsky, Channing J. Der, Walid A. Houry, Stanley Lipkowitz, Edwin J. Iwanowicz & Lee M. Graves. (2022) Characterization of TR ‐107, a novel chemical activator of the human mitochondrial protease ClpP . Pharmacology Research & Perspectives 10:4.
Crossref
Alessandro Allegra, Emanuela Sant’Antonio, Caterina Musolino & Roberta Ettari. (2022) New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies. Current Medicinal Chemistry 29:14, pages 2412-2437.
Crossref
Yali Fan, Jiandong Wang, Ziwei Fang, Stuart R. Pierce, Lindsay West, Allison Staley, Katherine Tucker, Yajie Yin, Wenchuan Sun, Weimin Kong, Varun Prabhu, Joshua E. Allen, Chunxiao Zhou & Victoria L. Bae-Jump. (2022) Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer. Frontiers in Oncology 12.
Crossref
Yiqun Zhang, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan & Wafik S. El-Deiry. (2021) EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia 23:8, pages 792-810.
Crossref
Erin R Bonner, Sebastian M Waszak, Michael A Grotzer, Sabine Mueller & Javad Nazarian. (2021) Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Neuro-Oncology 23:4, pages 542-556.
Crossref
Varun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, Lanlan Zhou, Marie Ralff, Jocelyn Ray, Aakash Jhaveri, Isacco Ferrarini, Young Lee, Cassandra Parker, Yiqun Zhang, Robyn Borsuk, Wen-I Chang, Joshua N. Honeyman, Fabio Tavora, Benedito Carneiro, Alexander Raufi, Kelsey Huntington, Lindsey Carlsen, Anna Louie, Howard Safran, Attila A. Seyhan, Rohinton S. Tarapore, Lee Schalop, Martin Stogniew, Joshua E. Allen, Wolfgang Oster & Wafik S. El-Deiry. (2020) ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia 22:12, pages 725-744.
Crossref
Kristen R. McSweeney, Laura K. Gadanec, Tawar Qaradakhi, Thushira Malindra Gammune, Peter Kubatka, Martin Caprnda, Julia Fedotova, Jozef Radonak, Peter Kruzliak & Anthony Zulli. (2020) Imipridone enhances vascular relaxation via FOXO1 pathway. Clinical and Experimental Pharmacology and Physiology 47:11, pages 1816-1823.
Crossref
Isabel Arrillaga-Romany, Yazmin Odia, Varun V Prabhu, Rohinton S Tarapore, Krystal Merdinger, Martin Stogniew, Wolfgang Oster, Joshua E Allen, Minesh Mehta, Tracy T Batchelor & Patrick Y Wen. (2020) Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology 22:1, pages 94-102.
Crossref
Lim, Greer, Lipkowitz & Takebe. (2019) Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers 11:8, pages 1087.
Crossref
Zonghui Ma, Ge Gao, Kunsen Fang & Haiying Sun. (2019) Development of Novel Anticancer Agents with a Scaffold of Tetrahydropyrido[4,3- d ]pyrimidine-2,4-dione . ACS Medicinal Chemistry Letters 10:2, pages 191-195.
Crossref
Christina Leah B. Kline, Jessica Wagner, Amriti Lulla, Marie D. Ralff, Avital Lev, Lanlan Zhou, Varun V. Prabhu, Martin Stogniew, Lee Schalop, Wolfgang Oster, Joshua E. Allen & Wafik S. El-Deiry. 2018. Early Drug Development. Early Drug Development 631 646 .
Avital Lev, Amriti R. Lulla, Brian C. Ross, Marie D. Ralff, Petr B. Makhov, David T. Dicker & Wafik S. El-Deiry. (2018) ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research 16:5, pages 754-766.
Crossref
Yoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, Christina Stuelten, Dan Crooks, Vishal N. Koparde, Samuel F. Gilbert, Celia Islam, Ashley Ubaldini, Yun Ji, Luca Gattinoni, Ferri Soheilian, Xiantao Wang, Markus Hafner, Jyoti Shetty, Bao Tran, Parthav Jailwala, Maggie Cam, Martin Lang, Donna Voeller, William C. Reinhold, Vinodh Rajapakse, Yves Pommier, Roberto Weigert, W. Marston Linehan & Stanley Lipkowitz. (2018) ONC201 kills breast cancer cells in vitro by targeting mitochondria . Oncotarget 9:26, pages 18454-18479.
Crossref
Avital Lev, Amriti R. Lulla, Jessica Wagner, Marie D. Ralff, Joshua B. Kiehl, Yan Zhou, Cyril H. Benes, Varun V. Prabhu, Wolfgang Oster, Igor Astsaturov, David T. Dicker & Wafik S. El-Deiry. (2017) Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget 8:47, pages 81776-81793.
Crossref
Joshua E. Allen, C. Leah B. Kline, Varun V. Prabhu, Jessica Wagner, Jo Ishizawa, Neel Madhukar, Avital Lev, Marie Baumeister, Lanlan Zhou, Amriti Lulla, Martin Stogniew, Lee Schalop, Cyril Benes, Howard L. Kaufman, Richard S. Pottorf, B. Rao Nallaganchu, Gary L. Olson, Fahd Al-Mulla, Madeleine Duvic, Gen Sheng Wu, David T. Dicker, Mala K. Talekar, Bora Lim, Olivier Elemento, Wolfgang Oster, Joseph Bertino, Keith Flaherty, Michael L. Wang, Gautam Borthakur, Michael Andreeff, Mark Stein & Wafik S. El-Deiry. (2016) Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7:45, pages 74380-74392.
Crossref
Yoshimi Endo GreerStanley Lipkowitz. (2016) ONC201: Stressing tumors to death. Science Signaling 9:415.
Crossref
Fiona O’Neill. 2016. Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance to Targeted Therapies Against Adult Brain Cancers 89 105 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.